Measures against Climate Change

Santen makes efforts to reduce CO₂ emissions aiming for net zero greenhouse gas emissions.

CO₂ emissions (Scope 1＋Scope 2 (market based)) in FY2024 were 34,870 t-CO₂, representing a 55.4% increase from FY2023. CO₂ emissions per unit of revenue (market based) were 116 t-CO₂ per billion yen, a 56.4% increase from FY2023, due to the start of test operations at the Suzhou Plant.

Fluorinated gases that contribute to global warming are also properly managed. In Japan, where most of these gases are used, emissions remain below the regulatory reporting thresholds.

In Japan, we assess not only Greenhouse Gas (CO₂) emissions from Santen, but also those from Scope 3, in other words, our supply chains resulting from the purchase of raw materials, the distribution of products, and the movement of employees and strive to reduce CO₂ emissions. From FY2023, to improve calculation accuracy, the boundary of Scope 3 Category 2 (Capital goods) expanded from “All of the facilities and sales offices in Japan” to “All of the facilities and sales offices in Japan and Santen Pharmaceutical (China) Co., Ltd.”. In addition, Scope 3 Category 3 (Fuel and energy related activities not included in Scope 1 and Scope 2) was revised from “emissions from electricity procurement” to “emissions from all fuels and energy procurement”. As a result, total Scope 3 CO₂ emissions amounted to 154,563 tons, and consolidated sales revenue were 515 t-CO₂ per billion yen in FY2024.